GLP1R-imaging in Hypoglycemia

  • STATUS
    Recruiting
  • End date
    Jan 1, 2022
  • participants needed
    12
  • sponsor
    Radboud University
Updated on 24 June 2021
gastric bypass
hyperinsulinemic hypoglycemia

Summary

Hyperinsulinemic hypoglycemia (HH) is a rare complication that occurs 1 to 5 years after gastric bypass surgery. The underlying mechanism of this complication is not yet completely understood. Changes in hormone levels, such as GLP1 after RYGB, nesidioblastosis or an increase in the number of beta cells may be one of the underlying causes. However, several study results are conflicting and it is hypothesized that the patient population with HH after RYGB is heterogeneous and several underlying causes may be present. In order to differentiate between hyperfunction with normal beta cell mass and a general or localized increase in beta cell mass we aim to compare quantitative 68Ga-exendin-4 PET imaging of the pancreas between patients with and without HH after RYGB. Thereby, investigators aim to increase the insight in the underlying mechanism of HH after RYGB. If different underlying causes can be diagnosed, treatment for HH can be optimized for patients.

Description

Hyperinsulinaemic hypoglycemia after bariatric surgery. Overweight and obesity are an increasing health problem globally and in the Netherlands, about 15% of the population in the Netherlands is obese. Obesity is associated with increased risk of morbidity, such as cardiovascular disease and type 2 diabetes (T2D). Weight loss is the most important intervention in obese patients, reducing obesity related morbidity and increasing life expectancy. Non-invasive weight loss interventions such as diet, lifestyle or medication only have a moderate effect which is short lived. Weight reducing surgery, i.e. bariatric surgery, is the only intervention that leads to persistent weight loss and is superior above conventional treatment. The most performed and preferred bariatric surgery is Roux-en-Y Gastric Bypass (RYGB), which is a food restrictive and malabsorptive procedure. Besides weight loss, metabolic improvement in T2D patients is an additional result after RYGB.

A frequent late complication of RYGB is the dumping syndrome and a rare late complication is hyperinsulinaemic hypoglycemia (HH). Reported incidences of dumping syndrome range from 20 to 70% of the patients. Dumping is a condition where food enters the small bowel too rapidly and can be divided into early and late dumping. Early dumping is due to rapid gastric emptying and comprises intestinal and vasomotor symptoms within minutes after food ingestion. Late dumping occurs 1 to 3 hours after a meal and the symptoms are partly caused by hypoglycemia.

Reported incidences of HH range from 0.2 to 1% after RYGB and is observed after gastric bypass procedures only. In HH plasma glucose concentrations reach values below 50 mg/dL (2.8 mmol/L) and adrenergic and neuroglucopenic symptoms occur, often occurring after a meal. After a meal or glucose challenge an early large glucose peak followed by an insulin peak is observed in HH patients. Additionally, an increased postprandial GLP1 level compared to RYGB controls without HH was observed. Low plasma glucose levels are also found in asymptomatic patients after RYGB in 30 to 50% of the patients.

The underlying mechanism of HH is not completely understood and several potential causes have been proposed, including, 1) An inappropriate increase of beta cell mass and function, that is persisting despite the increased insulin sensitivity after RYGB, 2) late dumping syndrome, i.e. an inappropriate insulin secretion following rapid food entry into the small intestine, 3) an inappropriate counter-regulatory glucagon response and 4) post-RYGB an increase in the incretin secretion (GLP1 and GIP).

Besides stimulation of the postprandial insulin secretion, GLP1 may induce beta cell hypertrophy or an increase in the number of beta cells by inhibiting apoptosis and increasing replication. Nesidioblastosis (beta cell hypertrophy, islet hyperplasia and increased beta cell mass) is associated with HH after RYGB in some cases, however, nesidioblastosis was not found in these patients and an overexpression of GLP1-receptors in individual islets was not found.

Proposed treatment options for HH after RYGB include diet therapy with a low-carbohydrate diet, drug therapy to inhibit carbohydrate digestion (acarbose) or to inhibit insulin secretion by beta cells (e.g. diaxozide, octreotide, pasireotide) or surgical treatment by a reconstruction of the gastric bypass or by a partial pancreatectomy. The effectiveness of these therapies vary among patients, we expect that the effectiveness of different treatments depends on the underlying cause of HH.

The different possible underlying mechanisms and different types of treatment suggest diverse causes of HH. In order to increase the insight in these causes and to be able to determine the best treatment for each patient in the future, the underlying cause(s) will be examined first in this study. In previous studies that assessed beta cell mass, only only pathological assessment of pancreas specimens was performed, because in vivo assessment was impossible. The control group was determined from patients undergoing a (partial) pancreatectomy for other diseases or post-mortem. However, ideally the control group would consist of patients who have had RYGB as well, without developing HH.

Recently, it became possible to assess beta cell mass in vivo by SPECT and PET imaging. In this study it is examined if this imaging technique can detect an increase in beta cell mass in patients suffering from persisting HH after RYGB. For this purpose we will compare beta cell mass in patients with and without HH after RYGB. Additionally, beta cell function and postprandial incretin responses will be determined in these subjects.

The results of this pilot study may lead to improved diagnostics and treatment options for persisting HH in bariatric patients in future.

Imaging of beta cells in vivo by GLP-1 receptor imaging by PET For specific non-invasive imaging of beta cells, investogators have developed a highly beta cell-specific radiolabeled exendin-based GLP-1 (glucagon-like peptide-1) analog which, after radiolabeling, can non-invasively be detected in the human body. GLP-1 is an incretin hormone that specifically binds to beta cells and is responsible for post-prandial insulin-secretion. Its specificity for beta cells has been shown and a linear correlation of the beta cell mass and the signal obtained with this tracer has been established.

GLP-1R imaging has been shown to be suitable for imaging of insulin producing pancreatic neuroendocrine tumours (IPPNET). Furthermore, the feasibility of visualization of transplanted beta cells with GLP-1R imaging has been shown by imaging of autologous islets transplanted into muscle.

Details
Condition Hypoglycemia, Hypocalcemia
Treatment 68Ga-NODAGA-exendin-4 PET/CT
Clinical Study IdentifierNCT03182192
SponsorRadboud University
Last Modified on24 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

All individuals
Signed informed consent
> 18
Additional for matched control group
RYGB at least 2 years ago
Normal glucose levels before and after RYGB
Score <7 on Sigstad's scoring system
Individual matched to HH group on age

Exclusion Criteria

All individuals
Anti-diabetic medication in the past 6 months
Treatment with synthetic exendin in the past 6 months
Liver failure
Pregnancy
Breast feeding
Kidney failure
Age < 18
No signed informed consent
Additional for matched control group
Any diabetic history
Previous diagnosed HH
Sigstad's dumping score >7
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note